American Shared Hospital Services (AMS) Stock AnalysisAMSAmerican Shared Hospital Services

American Shared Hospital Services is a provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. Its segments include Leasing and Retail. The Leasing segment comprises the Company’s medical equipment leasing. The Retail segment comprises facilities in Peru and Ecuador. Its Proton Beam Radiation Therapy Operations is an alternative to traditional external beam, photon-based radiation delivered by linear accelerators. Its Gamma Knife stereotactic radiosurgery, a non-invasive procedure, is an alternative to conventional brain surgery and/or radiation therapy. The Gamma Knife treats selected malignant and benign brain tumors, arteriovenous malformations, and functional disorders including trigeminal neuralgia (facial pain). It can be an adjunct to conventional brain surgery, radiation therapy, or chemotherapy. The Company provides radiation therapy services both domestically and internationally. It operates in the Industrials sector (SERVICES-MEDICAL LABORATORIES industry).

American Shared Hospital Services (AMS) is currently not a strong buy due to its low RSI of 24.755, indicating oversold conditions, and a significant year-to-date change of -37.22%. While the recent revenue growth of 19.2% year-over-year in Q2 2026 is promising, the company has been consistently reporting net losses, with a net income of -612,000 USD in Q1 2026 and -998,000 USD in Q2 2026. The forward P/E ratio of 44.64 suggests that the stock may be overvalued relative to its earnings potential. The main risk is the continued decline in stock price, as evidenced by a 5-day change of -6.38%.